Ceftolozane sulfate
Code | Size | Price |
---|
TAR-T30790-5mg | 5mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Ceftolozane Sulfate may be used to treat urinary tract infections.
CAS:
936111-69-2
Formula:
C23H31N12O12S3
Molecular Weight:
763.75
Purity:
0.98
SMILES:
[O-]S([O-])(=O)=O.[H][C@]12SCC(C[n+]3cc(NC(=O)NCCN)c(N)n3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)c1nsc(N)n1)C(O)=O
References
1. Kaye KS, Pogue JM. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management. Pharmacotherapy. 2015 Oct;35(10):949-62. doi: 10.1002/phar.1636. Review. PubMed PMID: 26497481.
2. Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis. 2015 May 15;60(10):1462-71. doi: 10.1093/cid/civ097. Epub 2015 Feb 10. PubMed PMID: 25670823; PubMed Central PMCID: PMC4412191.
3. Golan Y. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. BMC Infect Dis. 2015 Aug 5;15:313. doi: 10.1186/s12879-015-1054-1. Review. PubMed PMID: 26243291; PubMed Central PMCID: PMC4526420.
4. Cluck D, Lewis P, Stayer B, Spivey J, Moorman J. Ceftolozane-tazobactam: A new-generation cephalosporin. Am J Health Syst Pharm. 2015 Dec 15;72(24):2135-46. doi: 10.2146/ajhp150049. Review. PubMed PMID: 26637512.